Assessment of quality of life in hypertension and its hearing on compliance

International Journal of Clinical Practice, Supplement

Volumn , Issue 92, 1997, Pages 19-22

  Testa, Marcia A ^a   Turner, Ralph R ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Phase V Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; CAPTOPRIL; ENALAPRIL; METHYLDOPA; NIFEDIPINE; PROPRANOLOL;

BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; FACE EDEMA; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; VISUAL IMPAIRMENT; WELLBEING; XEROSTOMIA;

EID: 33749309236     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
2. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
3. Amery A, Birkenhager W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 15: 1349-1354.
4. Hosie J, Wicklund I. Managing hypertension in general practice. can we do better? J Hum Hypertens 1995; 9(S2): 515-18.
5. The Fifth Report on the Joint National Committee on Detection. Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-183.
6. Croog SH, Levine S, Testa MA et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.
7. Wiklund I. Quality of life and cost-effectiveness in the treatment of hypertension. J Clin Pharm Ther 1994; 19: 81-87.
8. Wiklund I. Hypertension. In: B Spilker, Ed. Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Philadelphia: Lippencott-Raven. 1996.
9. Dimenäs ES, Wiklund IK, Dahlöf CG et al. Differences in the subjective wellbeing and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 1989; 7: 885-890.
10. Tibblin G, Bengtsson C, furunes B, Lapidus L. Symptoms by age and sex. The population studies of men and women in Gothenburg, Sweden. Scan J Primary Hlth Care 1990; 8: 9-17.
11. Anderson RB, Testa MA. Symptom distress checklists as a component of quality of life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician. Drug Info J 1994; 28: 89-114.
12. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 344: 835-840.
13. Testa MA, Nackley JF. Methods for quality-of-life studies. Ann Rev Public Health 1994; 15: 535-559.
14. Omvik P, Thaulow E, Herland O, Eide I, Midha R, Turner R. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients. A multicentre study. J Hypertens 1993; 11: 103-113.
15. Testa MA, Hollenberg NK, Anderson RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991; 4: 363-73.
16. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. The Quality of Life Hypertension Study Group. Quality of life and antihypertensive therapy in men. A comparison of captopril and enalapril. W Engl J Med 1993; 328: 907-913.
17. Turner RR, Testa MA, Simonson DC et al. Ca channel blockers and quality of life: nifedipine GITS vs. amlodipine in mild to moderate hypertension. Paper presented at the Drug Information Association Quality of Life Symposium, Charleson, SC, May, 1997.
18. Nackley JF, Lenderking WR, Testa MA. The effects of antihypertensive therapy on cognitive functioning and quality of life. Paper presented at the Drug Information Association Quality of Life Symposium, Boston, MA, 1996.